RNA Biosensors for Real-Time Diabetes Detection and Monitoring
RNA biosensors for diabetes could allow earlier diagnosis and better personalised care. Explore the power of AI monitoring and next-generation molecular diagnostics.
HealthTech & AI
Discover how artificial intelligence and healthtech are transforming healthcare and drug development.
Google SensorFM: One Trillion Minutes of Wearable AI Data
Google SensorFM was pretrained on over one trillion minutes of wearable data. Discover what this AI foundation model could mean for digital health and pharma.
Anthropic’s Gates Foundation Partnership and Healthcare AI
See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
Claude Science: An Operating System for AI-Driven Pharma R&D
Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.
AI and Neuroscience. Why Big Pharma Is Betting on the Brain
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
How AI Is Reshaping Data Integrity in Pharma Manufacturing
Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
AI in Pharma: Hype vs. What Actually Works
Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.
Could Biological Age Become Pharma's Most Important Biomarker?
New research shows biomarkers of biological age predict mortality and hospitalisation better than chronological age, opening new opportunities for pharma innovation.
